PA
Profund Advisors Portfolio holdings
AUM
$2.78B
1-Year Return
29.53%
This Quarter Return
+15.99%
1 Year Return
+29.53%
3 Year Return
+153.44%
5 Year Return
+262.59%
10 Year Return
+738.89%
AUM
$2.57B
AUM Growth
+$240M
(+10%)
Cap. Flow
+$2.26M
Cap. Flow
% of AUM
0.09%
Top 10 Holdings %
Top 10 Hldgs %
34.11%
Holding
1,211
New
84
Increased
525
Reduced
539
Closed
63
Top Buys
| 1 |
NVIDIA
NVDA
|
$23.5M |
| 2 |
Linde
LIN
|
$16.4M |
| 3 |
Broadcom
AVGO
|
$3.16M |
| 4 |
Advanced Micro Devices
AMD
|
$2.67M |
| 5 |
Qualcomm
QCOM
|
$1.54M |
Top Sells
| 1 |
Exxon Mobil
XOM
|
$6.7M |
| 2 |
Microsoft
MSFT
|
$5.59M |
| 3 |
Chevron
CVX
|
$4.56M |
| 4 |
Meta Platforms (Facebook)
META
|
$4.45M |
| 5 |
Viking Therapeutics
VKTX
|
$3.77M |
Sector Composition
| 1 | Technology | 42.5% |
| 2 | Healthcare | 12.67% |
| 3 | Consumer Discretionary | 11.07% |
| 4 | Communication Services | 9.14% |
| 5 | Financials | 5.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
251
BioMarin Pharmaceuticals
BMRN
$11.1B
| $1.41M | 0.06% |
16,158
+914
| +6% | +$79.8K |
|
252
Ironwood Pharmaceuticals
IRWD
$188M
| $1.41M | 0.05% |
161,855
+42,371
| +35% | +$369K |
|
253
AT&T
T
$212B
| $1.41M | 0.05% |
80,037
-8,474
| -10% | -$149K |
|
254
Denali Therapeutics
DNLI
$2.26B
| $1.41M | 0.05% |
68,474
+14,799
| +28% | +$304K |
|
255
Amicus Therapeutics
FOLD
$2.46B
| $1.4M | 0.05% |
119,258
-13,148
| -10% | -$155K |
|
256
Dynavax Technologies
DVAX
$1.18B
| $1.4M | 0.05% |
113,133
+20,142
| +22% | +$250K |
|
257
IDEAYA Biosciences
IDYA
$2.38B
| $1.4M | 0.05% |
31,922
-54
| -0.2% | -$2.37K |
|
258
Arrowhead Research
ARWR
$4.02B
| $1.4M | 0.05% |
48,960
-14,593
| -23% | -$417K |
|
259
Air Products & Chemicals
APD
$64.5B
| $1.4M | 0.05% |
5,768
-285
| -5% | -$69K |
|
260
Arcellx
ACLX
$4.03B
| $1.39M | 0.05% |
20,033
+1,436
| +8% | +$99.9K |
|
261
Biohaven
BHVN
$1.68B
| $1.39M | 0.05% |
25,453
-19,060
| -43% | -$1.04M |
|
262
3M
MMM
$82.7B
| $1.39M | 0.05% |
15,664
+582
| +4% | +$51.6K |
|
263
Iovance Biotherapeutics
IOVA
$901M
| $1.39M | 0.05% |
93,650
-108,776
| -54% | -$1.61M |
|
264
Syndax Pharmaceuticals
SNDX
$1.47B
| $1.39M | 0.05% |
58,247
-6,935
| -11% | -$165K |
|
265
Alnylam Pharmaceuticals
ALNY
$59.4B
| $1.39M | 0.05% |
9,270
+938
| +11% | +$140K |
|
266
Skyworks Solutions
SWKS
$11.2B
| $1.38M | 0.05% |
12,781
+1,747
| +16% | +$189K |
|
267
Rocket Pharmaceuticals
RCKT
$354M
| $1.38M | 0.05% |
51,148
+16,677
| +48% | +$449K |
|
268
Carvana
CVNA
$50.9B
| $1.38M | 0.05% |
15,665
-4,945
| -24% | -$435K |
|
269
Teradyne
TER
$19.1B
| $1.38M | 0.05% |
12,198
+1,615
| +15% | +$182K |
|
270
Altimmune
ALT
$314M
| $1.37M | 0.05% |
+134,842
| New | +$1.37M |
|
271
Ionis Pharmaceuticals
IONS
$9.76B
| $1.37M | 0.05% |
31,570
+2,497
| +9% | +$108K |
|
272
Nutanix
NTNX
$18.7B
| $1.36M | 0.05% |
22,022
-2,465
| -10% | -$152K |
|
273
DocuSign
DOCU
$16.1B
| $1.36M | 0.05% |
22,764
+897
| +4% | +$53.4K |
|
274
Amphenol
APH
$135B
| $1.35M | 0.05% |
23,390
-1,082
| -4% | -$62.4K |
|
275
PTC Therapeutics
PTCT
$4.55B
| $1.34M | 0.05% |
46,145
-9,233
| -17% | -$269K |
|